Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease (COPD)

In brief

This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive pulmonary disease.

Key facts

Study ID

NCT00821093

Run by

Novartis Pharmaceuticals

People needed

1123

Starts

2009-01-01

Expected to finish

2009-10-01

Last updated by the study team

2011-08-18

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged ≥ 40 years
• Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate to severe as classified by the GOLD Guidelines, 2007) and:
• Smoking history of at least 10 pack years
• Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and ≥ 30% of the predicted normal value at screening
• Post-bronchodilator FEV1/FVC (forced vital capacity) < 70% at screening

You may not qualify if…

• Patients who have received systemic corticosteroids for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period
• Patients requiring long-term oxygen therapy (> 15 h a day) for chronic hypoxemia
• Patients who have had a respiratory tract infection within 6 weeks prior to screening
• Patients with concomitant pulmonary disease
• Patients with a history of asthma
• Patients with diabetes Type I or uncontrolled diabetes Type II
• Any patient with lung cancer or a history of lung cancer
• Any patient with active cancer or a history of cancer with less than 5 years disease-free survival time
• Patients with a history of long QT syndrome or whose QTc interval (Fridericia's) measured at screening is prolonged
• Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period
• Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements
• Other protocol-defined inclusion/exclusion criteria applied to the study.

Where it is running

• Novartis Investigator Site — Fairhope, Alabama, United States
• Novartis Investigator Site — Jasper, Alabama, United States
• Novartis Investigator Site — Mobile, Alabama, United States
• Novartis Investigator Site — Glendale, Arizona, United States
• Novartis Investigator Site — Phoenix, Arizona, United States
• Novartis Investigator Site — Buena Park, California, United States
• Novartis Investigator Site — Encinitas, California, United States
• Novartis Investigator Site — Fullerton, California, United States
• Novartis Investigator Site — Rancho Mirage, California, United States
• Novartis Investigator Site — Riverside, California, United States
• Novartis Investigator Site — San Diego, California, United States
• Novartis Investigator Site — Torrance, California, United States
• Novartis Investigator Site — Walnut Creek, California, United States
• Novartis Investigator Site — Fort Collins, Colorado, United States
• Novartis Investigative Site — Wheat Ridge, Colorado, United States
• Novartis Investigative Site — Stamford, Connecticut, United States
• Novartis Investigative Site — Newark, Delaware, United States
• Novartis Investigative Center — Clearwater, Florida, United States
• Novartis Investigative Site — Pensacola, Florida, United States
• Novartis Investigative Site — Pensacola, Florida, United States
• Novartis Investigative Site — South Miami, Florida, United States
• Novartis Investigative Site — Tamarac, Florida, United States
• Novartis Investigative Site — Tampa, Florida, United States
• Novartis Investigative Site — Tampa, Florida, United States
• Novartis Investigator Site — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.